Followers | 8 |
Posts | 849 |
Boards Moderated | 0 |
Alias Born | 03/14/2017 |
Wednesday, April 25, 2018 4:20:48 PM
Take a good look at what OWCP has been doing instead of babysitting inpatient investors:
https://patentimages.storage.googleapis.com/8f/73/66/91ea24f64b0281/US20180042845A1.pdf
https://patentimages.storage.googleapis.com/2f/aa/58/aa80e19d0880d5/US20170367875A1.pdf
https://patentimages.storage.googleapis.com/b8/1c/09/45c55ac2ed6c11/US20180042890A1.pdf
And then, on February 18, 2018, OWC Pharmaceutical Research Corp., OTCQB: OWCP, appointed Dr. Oron Yacoby Zeevi as its Chief Scientific Officer (CSO).
Dr Zeevi is an expert in this kind of R&D and getting patents granted and it's very likely that she read every patent application as well as reviewed all of the work OWCP had done before joining the OWCP team. There's no way she would have joined OWCP if it was not legit.
Dr. Oron Yacoby Zeevi, age 57, Chief Scientific Officer : Dr. Yacoby Zeevi has more than 20 years of extensive scientific experience with both private and publicly listed companies in the biopharmaceutical industry. In 2008, Dr. Yacoby Zeevi joined Neuroderm Ltd (Nasdaq: NDRM), a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders as the Vice President of Research and was promoted to the position of VP R&D. From October 2016 until her recent departure, she served as Chief Scientific Officer of Neuroderm, which was sold to Mitsubishi Tanabe Pharma for US $1.1 billion in July 2017.
Dr. Yacoby Zeevi, is the inventor of over 50 issued patents and patents pending, Her expertise lies in industry-oriented innovation and scientific research, accelerating and orchestrating the evolution of new ideas through R&D PoC, IP, CMC, early efficacy and safety trials, regulatory affairs and market landscape mapping in fields of unmet medical needs, towards development of commercially viable pharmaceutical or agricultural products. Dr. Yacobi Zeevi earned her PHD in micro biology and immunology from the Ben Gurion University of Be’er Sheva, Israel and also holds a degree of Doctor in Veterinary Medicine from the Hebrew University of Jerusalem
Dr. Yehuda Baruch who, will now assume the role of Chief Medical and Regulatory Officer of the OWC Pharmaceutical Research Corp. commented:
"I am very pleased that we have reached a stage in our development where we were able to recruit a scientist of the caliber and background of Dr. Yacoby Zeevi. Her past scientific experience and achievements will greatly benefit our endeavors."
Dr. Yacoby Zeevi commented, "I am very proud to join OWCP and cooperate with their excellent management team in order to advance the Company to the next level. The Company has achieved a great deal in its clinical development to date and I am sure I can help in accelerating its growth."
Mr. Mordechai Bignitz, Chief Executive Officer, commented on the appointment, "I am proud and honored to have Dr. Zeevi agree to join OWCP and assume the role of CSO. She brings with her immense pharmaceutical discovery and development knowledge, a unique set of skills and an exceptional track record, which contributed significantly to the success of her previous company. Her addition will complement our management team extremely well."
Read it all, do your own DD.
$OWCP Long and Strong... GOING TO BE HUGE!
YOU ARE A GHOST DRIVING A MEAT COATED SKELETON MADE FROM STARDUST RIDING A ROCK FLOATING THROUGH SPACE.
FEAR NOTHING!
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM